Among the neurological adverse events (nAEs) reported with PD‐1 inhibitors, peripheral neuropathy, dizziness, myasthenia gravis, cerebrovascular accidents, and encephalitis were the most frequent. This evidence concerns the gene PDCD1 and myasthenia gravis.